Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study.
immunotherapy
metastatic renal cell carcinoma
stereotactic body radiotherapy
targeted therapy
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
04
2019
revised:
29
08
2019
accepted:
31
08
2019
entrez:
2
11
2019
pubmed:
2
11
2019
medline:
2
11
2019
Statut:
epublish
Résumé
Tyrosine kinase inhibitors (TKIs) and checkpoint inhibitors have been established as effective treatment for metastatic renal cell carcinoma (mRCC), but only a minority of patients achieve complete response. Additional strategies are necessary to improve these agents' efficacy. Patients with stable disease for at least 4 months on TKI or checkpoint inhibitors were included. Stereotactic body radiotherapy (SBRT) was delivered to an organ with comparable lesions, where one lesion was in the treatment target and the other one was intentionally left untreated (control lesion). Response in both lesions was scored using the Response Evaluation Criteria in Solid Tumors V.1.1 criteria 2 months after completion of SBRT. The primary endpoint was the rate of SBRT adverse events, and the secondary endpoints included the rate of reduction in target lesion size. 17 patients were enrolled (14 men and 3 women, median age: 54.5 years old). SBRT was delivered to the lungs (n=5), bones (n=4), lymph nodes (n=4), liver (n=1), primary renal cell carcinoma (RCC) (n=1) and locally recurrent RCC (n=2). The equivalent dose in 2 Gy with an alpha to beta ratio of 2.6 was 114 Gy. With a median follow-up of 8 months, the cumulative rate of SBRT-related toxicity (grade 1) was 12% (n=2), consisting of oesophagitis and skin erythema. No grade 2 or higher toxicity was detected. Radiographic response in the target lesion was seen in 13 patients (76%), with complete response in 5 (29%) patients and partial response in 8 (47%), including abscopal effect in 1 patient. Control lesions remained stable in 16 patients. The difference between response in the target and control lesions as judged by the mean sizes of these lesions before and at 2 months after SBRT was statistically significant (p<0.01). Fraction size of 10 Gy or greater was associated with complete response (p<0.01). Extracranial SBRT in patients with mRCC treated with TKI or checkpoint inhibitors is well tolerated and could be effective. NCT02864615.
Sections du résumé
BACKGROUND
BACKGROUND
Tyrosine kinase inhibitors (TKIs) and checkpoint inhibitors have been established as effective treatment for metastatic renal cell carcinoma (mRCC), but only a minority of patients achieve complete response. Additional strategies are necessary to improve these agents' efficacy.
METHODS
METHODS
Patients with stable disease for at least 4 months on TKI or checkpoint inhibitors were included. Stereotactic body radiotherapy (SBRT) was delivered to an organ with comparable lesions, where one lesion was in the treatment target and the other one was intentionally left untreated (control lesion). Response in both lesions was scored using the Response Evaluation Criteria in Solid Tumors V.1.1 criteria 2 months after completion of SBRT. The primary endpoint was the rate of SBRT adverse events, and the secondary endpoints included the rate of reduction in target lesion size.
RESULTS
RESULTS
17 patients were enrolled (14 men and 3 women, median age: 54.5 years old). SBRT was delivered to the lungs (n=5), bones (n=4), lymph nodes (n=4), liver (n=1), primary renal cell carcinoma (RCC) (n=1) and locally recurrent RCC (n=2). The equivalent dose in 2 Gy with an alpha to beta ratio of 2.6 was 114 Gy. With a median follow-up of 8 months, the cumulative rate of SBRT-related toxicity (grade 1) was 12% (n=2), consisting of oesophagitis and skin erythema. No grade 2 or higher toxicity was detected. Radiographic response in the target lesion was seen in 13 patients (76%), with complete response in 5 (29%) patients and partial response in 8 (47%), including abscopal effect in 1 patient. Control lesions remained stable in 16 patients. The difference between response in the target and control lesions as judged by the mean sizes of these lesions before and at 2 months after SBRT was statistically significant (p<0.01). Fraction size of 10 Gy or greater was associated with complete response (p<0.01).
CONCLUSION
CONCLUSIONS
Extracranial SBRT in patients with mRCC treated with TKI or checkpoint inhibitors is well tolerated and could be effective.
TRIAL REGISTRATION NUMBER
BACKGROUND
NCT02864615.
Identifiants
pubmed: 31673426
doi: 10.1136/esmoopen-2019-000535
pii: S2059-7029(20)30119-8
pmc: PMC6802957
doi:
Banques de données
ClinicalTrials.gov
['NCT02864615']
Types de publication
Journal Article
Langues
eng
Pagination
e000535Informations de copyright
© Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Oncoimmunology. 2015 May 27;4(10):e1042198
pubmed: 26464810
Radiat Oncol J. 2016 Jun;34(2):128-34
pubmed: 27306772
Adv Drug Deliv Rev. 2017 Jan 15;109:3-14
pubmed: 27932046
Science. 2003 May 16;300(5622):1155-9
pubmed: 12750523
Lancet Oncol. 2014 Apr;15(4):e170-7
pubmed: 24694640
Cancer. 1997 Dec 15;80(12 Suppl):2519-28
pubmed: 9406705
Clin Genitourin Cancer. 2017 Dec;15(6):e1069-e1072
pubmed: 28882737
Cancer. 2009 May 15;115(10 Suppl):2282-9
pubmed: 19402071
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1749-55
pubmed: 21640509
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Clin Genitourin Cancer. 2017 Apr;15(2):183-187
pubmed: 27789182
Am J Clin Oncol. 2013 Dec;36(6):589-95
pubmed: 22868242
Crit Rev Oncol Hematol. 2017 Sep;117:48-56
pubmed: 28807235
Radiother Oncol. 1984 Dec;2(4):317-23
pubmed: 6395213
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Clin Genitourin Cancer. 2012 Sep;10(3):196-8
pubmed: 22409865
Pract Radiat Oncol. 2015 Nov-Dec;5(6):e589-e596
pubmed: 26142027
Acta Oncol. 2006;45(4):493-7
pubmed: 16760190
J Clin Oncol. 2006 Jul 1;24(19):3101-6
pubmed: 16809736